secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0000950170-23-003847
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma dismisses KPMG as auditor, appoints Ernst & Young
---------------------------------------------------------------

- Audit committee and board approved dismissal of KPMG on February 22, 2023.
- KPMG's reports for fiscal years ended March 31, 2022 and 2021 were unqualified with no adverse opinions.
- No disagreements or reportable events occurred between the company and KPMG during the relevant periods.
- Board approved engagement of Ernst & Young LLP as new independent auditor for fiscal year ending March 31, 2023.
- KPMG furnished a letter to the SEC agreeing with the company's disclosures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023003847/0000950170-23-003847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023003847/acst-20230222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-003847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer